STR


Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.
References in periodicals archive ?
Burnham Jake D & Kendall S, 1650 Kellogg Rd; STR - New single family dwelling, (demo old dwelling); $229,850.
Bruce Wiechert Custom Homes Inc, 6132 Graystone Loop; STR - New single family residence; $259,774.
Cummins Investments Llc, 1060 53RD ST; STR - New single family residence; $161,563.
Bruce Wiechert Custom Homes Inc, 6068 Graystone Loop; STR - single family residence; $261,267.
STR is an investigational, targeted cancer therapeutic that delivers radiation directly to cancer in the bone and bone marrow, sparing other tissues from radiation's effects.
The Company's product pipeline includes STR, currently in a pivotal Phase III clinical trial for patients with primary refractory multiple myeloma, and NX 473, a next-generation platinum therapy that the Company plans to evaluate in the treatment of patients with advanced lung and colorectal cancers.
Factors that could affect the Company's actual results include the availability of working capital and financing sources for the development of NeoRx's business, the progress and costs of clinical trials and the timing of regulatory approvals, the availability of clinical materials from third-party suppliers, NeoRx's ability to manufacture STR in a timely and cost-effective manner, NeoRx's ability to successfully commercialize product candidates, and other risks and uncertainties described in NeoRx's current and periodic reports filed with the Securities and Exchange Commission, including NeoRx's Annual Report on Form 10-K for the year ended December 31, 2003, and Quarterly Report on Form 10- Q for the quarter ended March 31, 2004.
Factors that could affect the Company's actual results include conditions in the capital markets in general and in the life science sector in particular, specifically those that may affect potential financing sources for the development of NeoRx's business, the progress and costs of clinical trials and the timing of regulatory approvals, the availability of clinical materials from third-party suppliers, NeoRx's ability to manufacture STR in a timely and cost-effective manner and commercialize products and other risks and uncertainties described in NeoRx's current and periodic reports filed with the Securities and Exchange Commission, including NeoRx's Annual Report on Form 10-K for the year ended December 31, 2003, and Quarterly Report on Form 10- Q for the quarter ended March 31, 2004.
NeoRx conducted phase I/II trials of STR in 83 patients with multiple myeloma at various clinical stages.
STR is an innovative targeted cancer therapeutic that delivers radiation directly to cancer in the bone and bone marrow, sparing other tissues from radiation's effects.
The Company has radiopharmaceutical manufacturing facilities in Denton, Texas, where it produces STR.
NeoRx and STR are registered trademarks or trademarks of NeoRx Corporation in the United States and/or foreign countries.